Deakin University
Browse

Regulation of glucose kinetics during intense exercise in humans: effects of α- and β-adrenergic blockade

Version 2 2024-06-17, 04:00
Version 1 2003-12-01, 00:00
journal contribution
posted on 2024-06-17, 04:00 authored by Kirsten HowlettKirsten Howlett, M Watt, M Hargreaves, M Febbraio
This study examined the effect of combined α- and β-adrenergic blockade on glucose kinetics during intense exercise. Six endurance-trained men exercised for 20 minutes at approximately 78% of their peak oxygen consumption (V<sub>O</sub> 2) following ingestion of a placebo (CON) or combined α- (prazosin hydrochloride) and β- (timolol maleate) adrenoceptor antagonists (BLK). Plasma glucose increased during exercise in CON (0 minutes: 5.5 ± 0.1; 20 minutes: 6.5 ± 0.3 mmol · L<sup>−1</sup>, P < .05). In BLK, the exercise-induced increase in plasma glucose was abolished (0 minutes: 5.7 ± 0.3; 20 minutes: 5.7 ± 0.1 mmol · L<sup>−1</sup>). Glucose kinetics were measured using a primed, continuous infusion of [6,6-<sup>2</sup>H] glucose. Glucose production was not different between trials; on average these values were 25.3 ± 3.9 and 30.9 ± 4.4 μmol · kg<sup>−1</sup> · min<sup>−1</sup> in CON and BLK, respectively. Glucose uptake during exercise was greater (P < .05) in BLK (30.6 ± 4.6 μmol · kg<sup>−1</sup> · min<sup>−1</sup>) compared with CON (18.4 ± 2.5 μmol · kg<sup>−1</sup> · min<sup>−1</sup>). In BLK, plasma insulin and catecholamines were higher (P < .05), while plasma glucagon was unchanged from CON. Free fatty acids (FFA) and glycerol were lower (P < .05) in BLK. These findings demonstrate that adrenergic blockade during intense exercise results in a blunted plasma glucose response that is due to enhanced glucose uptake, with no significant change in glucose production.<br>

History

Related Materials

Location

Philadelphia, Pa.

Language

eng

Notes

Available online 27 November 2003.

Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2003, Elsevier Inc.

Journal

Metabolism, clinical and experimental

Volume

52

Pagination

1615-1620

ISSN

0026-0495

eISSN

1532-8600

Issue

12

Publisher

W B Saunders Co

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC